Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Apricitabine does not select additional drug resistance mutations in tissue culture in human immunodeficiency virus type 1 variants containing K65R, M184V, or M184V plus thymidine analogue mutations.

Oliveira M, Moisi D, Spira B, Cox S, Brenner BG, Wainberg MA.

Antimicrob Agents Chemother. 2009 Apr;53(4):1683-5. doi: 10.1128/AAC.01168-08. Epub 2009 Feb 17.

2.
3.

Novel drug resistance pattern associated with the mutations K70G and M184V in human immunodeficiency virus type 1 reverse transcriptase.

Bradshaw D, Malik S, Booth C, Van Houtte M, Pattery T, Waters A, Ainsworth J, Geretti AM.

Antimicrob Agents Chemother. 2007 Dec;51(12):4489-91. Epub 2007 Sep 17.

4.

Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.

Zhang Z, Walker M, Xu W, Shim JH, Girardet JL, Hamatake RK, Hong Z.

Antimicrob Agents Chemother. 2006 Aug;50(8):2772-81.

5.

NNRTI-selected mutations at codon 190 of human immunodeficiency virus type 1 reverse transcriptase decrease susceptibility to stavudine and zidovudine.

Paolucci S, Baldanti F, Campanini G, Cancio R, Belfiore A, Maga G, Gerna G.

Antiviral Res. 2007 Nov;76(2):99-103. Epub 2007 Jul 2.

PMID:
17640745
7.

Resistance profile of the new nucleoside reverse transcriptase inhibitor apricitabine.

Cahn P, Wainberg MA.

J Antimicrob Chemother. 2010 Feb;65(2):213-7. doi: 10.1093/jac/dkp422. Epub 2009 Dec 9. Review.

PMID:
20007333
8.

Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy.

Betancor G, Garriga C, Puertas MC, Nevot M, Anta L, Blanco JL, Pérez-Elías MJ, de Mendoza C, Martínez MA, Martinez-Picado J, Menéndez-Arias L; Resistance Platform of the Spanish AIDS Research Network (ResRIS), Iribarren JA, Caballero E, Ribera E, Llibre JM, Clotet B, Jaén A, Dalmau D, Gatel JM, Peraire J, Vidal F, Vidal C, Riera M, Córdoba J, López Aldeguer J, Galindo MJ, Gutiérrez F, Álvarez M, García F, Pérez-Romero P, Viciana P, Leal M, Palomares JC, Pineda JA, Viciana I, Santos J, Rodríguez P, Gómez Sirvent JL, Gutiérrez C, Moreno S, Pérez-Olmeda M, Alcamí J, Rodríguez C, del Romero J, Cañizares A, Pedreira J, Miralles C, Ocampo A, Morano L, Aguilera A, Garrido C, Manuzza G, Poveda E, Soriano V.

Retrovirology. 2012 Aug 13;9:68. doi: 10.1186/1742-4690-9-68.

9.

A novel genetic pathway of human immunodeficiency virus type 1 resistance to stavudine mediated by the K65R mutation.

García-Lerma JG, MacInnes H, Bennett D, Reid P, Nidtha S, Weinstock H, Kaplan JE, Heneine W.

J Virol. 2003 May;77(10):5685-93.

10.

Trends in HIV-1 reverse transcriptase resistance-associated mutations and antiretroviral prescription data from 2003-2010.

Miller MD, Haddad M, Su C, Gibbs C, McColl DJ, Guyer B.

Antivir Ther. 2012;17(6):993-9. doi: 10.3851/IMP2266. Epub 2012 Jul 26.

PMID:
22837442
11.
12.

The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors.

Miller V, Stürmer M, Staszewski S, Gröschel B, Hertogs K, de Béthune MP, Pauwels R, Harrigan PR, Bloor S, Kemp SD, Larder BA.

AIDS. 1998 May 7;12(7):705-12.

PMID:
9619801
13.

R211K and L214F do not invariably confer high level phenotypic resistance to thymidine analogs in zidovudine-naive patients with M184V.

Torti C, Gilleece Y, Hertogs K, Gazzard BG, Pozniak AL.

J Acquir Immune Defic Syndr. 2001 Apr 15;26(5):514-5. No abstract available.

PMID:
11391177
14.

Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine.

Izopet J, Bicart-See A, Pasquier C, Sandres K, Bonnet E, Marchou B, Puel J, Massip P.

J Med Virol. 1999 Dec;59(4):507-11.

PMID:
10534734
16.

Quantification of the effects on viral DNA synthesis of reverse transcriptase mutations conferring human immunodeficiency virus type 1 resistance to nucleoside analogues.

Bouchonnet F, Dam E, Mammano F, de Soultrait V, Henneré G, Benech H, Clavel F, Hance AJ.

J Virol. 2005 Jan;79(2):812-22.

17.
18.

Mechanisms by which the G333D mutation in human immunodeficiency virus type 1 Reverse transcriptase facilitates dual resistance to zidovudine and lamivudine.

Zelina S, Sheen CW, Radzio J, Mellors JW, Sluis-Cremer N.

Antimicrob Agents Chemother. 2008 Jan;52(1):157-63. Epub 2007 Oct 29.

19.
20.

Supplemental Content

Support Center